Andrew Young

Andrew Young is the current Chief Scientific Officer at Intarcia Therapeutics. Andrew has also previously served as the VP and Head Enteroendocrine Biology at GlaxoSmithKline, CMO at Leptos Biomedical, and VP Sr Research Fellow at Amylin Pharmaceuticals. In addition, they have also co-founded Phoundry Pharmaceuticals Inc and Satiogen.

Andrew received their undergraduate degree in Physiology from The University of Auckland in 1987. Andrew then went on to complete their PhD in Physiology from the same school in 1989. After completing their PhD, Andrew lectured in Physiology at The University of Auckland for 2 years before joining Amylin Pharmaceuticals in 1991.

At Amylin Pharmaceuticals, Andrew co-authored a peptide hormone discovery initiative which found several novel ligands. Andrew also was responsible for in vivo screening for novel utilities of those and known peptide ligands. Andrew remained at Amylin until 2007 when they left to become the CMO of Leptos Biomedical.

After less than a year at Leptos Biomedical, Andrew left to join GlaxoSmithKline as the VP and Head Enteroendocrine Biology. In this position, they were responsible for overseeing the preclinical and clinical programs of an active antiobesity device. Andrew remained with GlaxoSmithKline until 2015 when they left to become the Chief Scientific Officer of Intarcia Therapeutics.

Andrew Young reports to Kurt Graves, Chairman, President & CEO. They are on a team with Anthony Hurley - Vice President, Global Technical Operations, Anders Vinther - Global Head of Technical Operations, and Thomas Alessi - Vice President, Development and Manufacturing.